Targeting glioblastoma: from dream to reality

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors

(2020) Zhen Chen et al.   Cancer Cell International

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study

(2020) Giuseppe Lombardi et al.   Cancers

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts

(2019) Masamichi Takahashi et al.   CANCER SCIENCE

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

(2019) Raghupathy Vengoji et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Novel IDH1-Targeted Glioma Therapies

(2019) Georg Karpel-Massler et al.   CNS DRUGS

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

(2018) Carmen Mecca et al.   DISEASE MARKERS

Molecular markers in glioma

(2017) Kirsten Ludwig et al.   JOURNAL OF NEURO-ONCOLOGY

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives

(2017) Wojciech Szopa et al.   Biomed Research International

The challenges associated with molecular targeted therapies for glioblastoma

(2016) Toni Rose Jue et al.   JOURNAL OF NEURO-ONCOLOGY

Treatment of Elderly Patients With Glioblastoma

(2015) Oren J. Zarnett et al.   JAMA Neurology

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

(2015) Emily Padfield et al.   Frontiers in Oncology

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma

(2014) Anna Joy et al.   PLoS One

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA